This article provides a summary of the available lipid-lowering therapies in the UK and how they fit into national guidelines. In addition, comparison is made between the current National Institute for Health and Care Excellence lipid modification guidelines and international guidance such as those published by the European Society of Cardiology/European Atherosclerosis Society and American Heart Association/American College of Cardiology.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors JC is sole author of this manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests JC has received speaker/advisory board fees from Amgen, Sanofi, Amyrt, Pfizer, Novartis, Akcea and Ionis. JC has received research grants from Amgen, Amyrt, Novartis and Silence Therapeutics. JC is a member of the Medical, Scientific and Research committee of HEART UK, the Cholesterol Charity.
Provenance and peer review Commissioned; externally peer reviewed.